Physician profile
Sarah E Graceffa
NPI 1669653630
$693.14
in general payments reported to CMS, 2019-2025
16 companies · $63.67 in 2025
The $63.67 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $387 · 2020: $76.87 · 2021: $26.72 · 2022: $16.85 · 2023: $22.25 · 2024: $99.38 · 2025: $63.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $185.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien Lp | $103.94 | 2019 | |
| Abbvie INC. | $102.79 | 2019-2023 | |
| Exeltis, USA INC. | $100.42 | 2019-2025 | Slynd |
| Therapeuticsmd, INC. | $76.94 | 2019-2022 | |
| Avion Pharmaceuticals | $52.69 | 2019-2021 | |
| Astellas Pharma US INC | $44.45 | 2020-2024 | Veozah |
| Mayne Pharma Commercial LLC | $30.31 | 2024 | |
| Duchesnay USA Incorporated | $29.70 | 2019 | |
| Amag Pharmaceuticals, INC. | $29.22 | 2019-2020 | |
| Allergan, INC. | $25.24 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $23.81 | 2025 | Myfembree |
| Sage Therapeutics, LLC | $16.25 | 2024 | |
| Kci USA, INC. | $16.16 | 2019 | |
| Roche Diagnostics Corporation | $15.44 | 2019 | |
| Merck Sharp & Dohme LLC | $14.10 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $11.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Graceffa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.